Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Wed, 17.12.2025
Heidelberg Pharma AG
Letter from the CEODear shareholders, partners, and friends of Heidelberg Pharma,
The past few months have been turbulent and difficult for Heidelberg Pharma. We have been confronted with events and changes that required swift and decisive action. Today, I am writing to you to explain where we stand - and, above all, why I am deeply convinced that [ … ]
Mon, 24.11.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), toda [ … ]
Thu, 06.11.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8
HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed in Coh [ … ]
Mon, 03.11.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial
Data reinforces the therapeutic potential and safety pr [ … ]
Thu, 23.10.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs
Enables more frequent engagement with FDA and eligibility for rolling review to support ex [ … ]
Thu, 09.10.2025
Heidelberg Pharma AG
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Leading ADC candidate HDP-101 continues to demonstrate favorable safety and tolerability profile; clinical trial progresses into ninth cohort with increased dose of 175 µg/kg
Delay in significant milestone payment leads to extensive cost-saving measures, including a 75% re [ … ]
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed
Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one pa [ … ]
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Milestone payment of USD 70 million from royalty financing agreement with HealthCare Royalty delayed as payment condition has not yet been met
Clinical Phase I/IIa trial with HDP-101 in Multiple Myelom [ … ]
Thu, 04.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Ladenburg, Germany, 4 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 10.07.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data
Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started
First patient in clinical study dosed with the second ATAC c [ … ]
